<DOC>
	<DOC>NCT01917279</DOC>
	<brief_summary>It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line Capecitabine plus Docetaxel chemotherapy in treatment of HER2-negative metastatic breast cancer(mBC).</brief_summary>
	<brief_title>Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasms by Site</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent obtained prior to initiation of any studyspecific procedures or treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. Female patients aged ≥ 18 years. Histologically confirmed and documented HER2negative metastatic breast cancer. Previously untreated firstline chemotherapy. Patients with at least one measurable lesion according to RECIST criteria at study entry. Documented ER/PgR status. Prior hormone therapy for metastatic disease is allowed but must stop before study entry. KPS&gt;70. Life expectancy of ≥12 weeks Previous chemotherapy for metastatic breast cancer. Prior adjuvant/neoadjuvant chemotherapy within 6 months prior to first study treatment administration. Prior (radical)radiotherapy for the treatment of metastatic disease or major surgical procedure within 28 days prior to the first study treatment, Inadequate bone marrow function: absolute neutrophil count (ANC): &lt;1.5 x 109/L, platelet count&lt;75 x 109/L or hemoglobin &lt;100g/L. Inadequate liver or renal function, defined as: 1. Serum (total) bilirubin &gt;2 x the upper limit of normal (ULN) for the institution 2. AST/SGOT or ALT/SGPT &gt;2.5 x ULN (&gt;5 x ULN in patients with liver metastases) 3. ALP &gt;2.5 x ULN at baseline (&gt;5 x ULN in patients with liver metastases). 4. Serum creatinine&gt;140umol/L. Pregnant or lactating females. Her2 positive (ICH +++ or FISH positive). Symptomatic cerebral parenchyma and/or leptomeningeal metastases. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer. Preexisting peripheral neuropathy ≥grade 1 according NCI CTCAE 4.0. Mental disease or other conditions affecting on the compliance of patients. Other serious disease or medical condition: 1. History of uncontrolled seizures, CNS disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent. 2. Congestive heart failure, or unstable angina, myocardial infarction within ≤6 months prior to the first study treatment, uncontrolled hypertension and high risk, uncontrolled arrhythmias. 3. Uncontrolled acute infection Inability to take or absorption oral medications. Concurrent or within 30 days using drugs of other clinical trials. Previous treatments containing Capecitabine (whether adjuvant or palliative treatment). Previous treatments containing docetaxel within 12 months. Known hypersensitivity to any of the study treatments or excipients. Any other conditions the research consider not appropriate to take part in the trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Tubulin Modulators</keyword>
	<keyword>Maintenance chemotherapy</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Docetaxel</keyword>
</DOC>